The Cyclic GMP-AMP Synthase pipeline drugs market research report outlays comprehensive information on the Cyclic GMP-AMP Synthase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclic GMP-AMP Synthase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Central Nervous System, Dermatology, and Genetic Disorders which include the indications Systemic Lupus Erythematosus, Autoimmune Disorders, Parkinson’s Disease, Neuroinflammation, Skin Inflammation, Vitiligo, and Aicardi-Goutieres Syndrome (AGS). It also reviews key players involved in Cyclic GMP-AMP Synthase targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclic GMP-AMP Synthase pipeline targets constitutes close to 16 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 2, 5, and 8 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Cyclic GMP-AMP Synthase overview
Cyclic GMP-AMP Synthase (CGAS) is a nucleotidyltransferase that catalyzes the formation of cyclic GMP-AMP (2′,3′-cGAMP) from ATP and GTP and plays a key role in innate immunity. Catalysis involves both the formation of a 2′,5′ phosphodiester linkage at the GpA step and the formation of a 3′,5′ phosphodiester linkage at the ApG step, producing c[G(2′,5′)pA(3′,5′)p]. Acts as a key DNA sensor: directly binds double-stranded DNA (dsDNA), inducing the formation of liquid-like droplets in which CGAS is activated, leading to synthesis of 2′,3′-cGAMP, a second messenger that binds to and activates STING1, thereby triggering type-I interferon production.
For a complete picture of Cyclic GMP-AMP Synthase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
